Goldman Sachs says this under-the-radar biotech play could more than double in value
Goldman Sachs believes that Biohaven offers investors an under-the-radar opportunity to invest in a potentially best-in-class kidney disease treatment. The bank initiated coverage on the biopharmaceutical company at a buy rating, setting a 12-month price target of $23. Shares of Biohaven have plunged 70% over the past 12 months and are down around 3% this…